


Laplace announces two major achievements: successful completion of patient enrollment in its US Early Feasibility Study (EFS) on its Trans-jugular (TJ) system and successful treatment of first two patients with their Trans-femoral (TF) delivery system.

Laplace announces two major achievements: successful completion of patient enrollment in its US Early Feasibility Study (EFS) on its Trans-jugular (TJ) system and successful treatment of first two patients with their Trans-femoral (TF) delivery system.


Laplace Interventional Inc. Announces Series C Financing of $22M for its Transcatheter Tricuspid Valve Technology







Laplace Interventional Inc. Announces Successful First in Human Procedure in Early Feasibility Study of its Transcatheter Tricuspid Valve Replacement Device.

The Series B financing was co-led by ShangBay Capital along with Features Capital in addition to participation from Engage Venture Partners, JWC Ventures and a global strategic investor. Laplace Interventional plans to use the funds raised from this round to pursue their First-in-Human (FIH) and clinical feasibility evaluation of its transcatheter valve system.

The Series A was led by a major strategic investor along with a significant investment from ShangBay Capital as well as other investors. Laplace Interventional plans to use the funds raised from this round towards achieving its preclinical milestones.
Caution: Laplace Interventional's TTVR system is for investigational use only and is NOT currently available for sale in US or any other geography.